6-溴-2,4-二氯喹啉 | 406204-90-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-2,4-二氯喹啉
• 英文名称: 6-bromo-2,4-dichloroquinoline
• CAS: 406204-90-8
• 化学式: C₉H₄BrCl₂N
• 分子量: 276.947
• InChiKey: CRFXLQFAIWSWIV-UHFFFAOYSA-N

物化性质

• 沸点：
  342.2±37.0 °C(Predicted)
• 密度：
  1.765±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  储存温度为2-8°C，并需保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  6-溴-2,4-二氯喹啉 在 sodium cyanoborohydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 18.0h， 生成 (6-bromo-2,4-dichloroquinolin-3-yl)methanol
  参考文献：
  名称：

  QUINOLINYL MODULATORS OF RORyt

  摘要：

  本发明涵盖了式I的化合物。 其中： R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中有定义。 该发明还涵盖了一种治疗或改善综合症、疾病或疾病的方法，其中所述的综合症、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还涵盖了通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。

  公开号：

  US20150111870A1
• 作为产物：
  描述：

  3-(4-溴苯胺基)-3-氧代丙酸甲酯 在 甲烷磺酸 、 四磷十氧化物 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.33h， 生成 6-溴-2,4-二氯喹啉
  参考文献：
  名称：

  Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

  摘要：

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.

  DOI：

  10.1021/jm502009h

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE<br/>[FR] COMPOSÉ POUR LE TRAITEMENT ET LA PROPHYLAXIE DE LA MALADIE DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013020993A1

  公开（公告）日：2013-02-14

  A compound of formula (I), as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in description and in claims, can be used as a medicament for the treatment of respiratory syncytial virus.

  式（I）的化合物，以及其药学上可接受的盐，其中R1至R10，A，Q，X和Y如描述和索赔中定义的，可用作治疗呼吸道合胞病毒的药物。
• [EN] QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE QUINOLÉINE, DE NAPHTALÈNE, DE QUINOLÉINE OU DE NAPHTALÈNE CONTRAINT AU NIVEAU CONFORMATION EN TANT QU'AGENTS ANTIMYCOBACTÉRIENS
  申请人：CHATTOPADHYAYA JYOTI

  公开号：WO2009091324A1

  公开（公告）日：2009-07-23

  The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the treatment of mycobacterial disease.

  该发明涉及一般式I、II、III、IV、V、VI、VII、VIII、IX、X的化合物，或其立体化学异构体或药学上可接受的盐，其N-氧化物形式或其前药。该化合物可用作治疗分枝杆菌病的药物。
• Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions
  作者：Ramakant A. Kardile、Aniket P. Sarkate、Avinash S. Borude、Rajendra S. Mane、Deepak K. Lokwani、Shailee V. Tiwari、Rajaram Azad、Prasad V.L.S. Burra、Shankar R. Thopate

  DOI：10.1016/j.bioorg.2021.105174

  日期：2021.10

  Further, in silico ADME prediction studies of all derivatives were found promising, signifying the drug like properties. In precise, the present investigation displays a new strategy to synthesize and emphasis on anticancer activities of conformationally constrained dibenzo[b,h][1,6] naphthyridine derivatives and Chromeno[3,2-c] quinoline derivatives in the context of cancer drug development and refinement

  新的非喜树碱 (non-CPT) 类构象受限、迄今未知的 7,12-二氢二苯并[ b,h ][1,6] 萘啶和 7 H - Chromeno[ 3,2-c ] 喹啉衍生物已被设计，合成并评估抗癌活性。针对人类癌细胞系（A549 和 MCF-7）的体外抗增殖评估显示出显着的细胞毒性。在衍生物 ( 8 – 24 ) 中，8 (IC 50 0.44 μM 和 IC 50 0.62 μM) 和12 (IC 50 0.69 μM 和 IC 500.54 μM) 被确定为分别针对 A-549 和 MCF-7 癌细胞系的最有希望的候选物。8和12 的Topo I 抑制活性表明，它们可能在未来被开发为潜在的抗癌分子，并通过与有效结合模式的对接分析进行合理化。此外，发现所有衍生物的计算机ADME 预测研究很有希望，表明具有类似药物的特性。准确地说，本研究展示了一种新的策略来合成和强调构象受限的二苯并[ b,h
• Identification and molecular modeling of new quinolin-2-one thiosemicarbazide scaffold with antimicrobial urease inhibitory activity
  作者：Mohammed A. I. Elbastawesy、Yaseen A. M. M. El-Shaier、Mohamed Ramadan、Alan B. Brown、Ashraf A. Aly、Gamal El-Din A. Abuo-Rahma

  DOI：10.1007/s11030-019-10021-0

  日期：2021.2

  A new series of 6-substituted quinolin-2-one thiosemicarbazides 6a–j has been synthesized. The structure of the target compounds was proved by different spectroscopic and elemental analyses. All the designed final compounds were evaluated for their in vitro activity against the urease-producing R. mucilaginosa and Proteus mirabilis bacteria as fungal and bacterial pathogens, respectively. Moreover, all compounds were in vitro tested as potential urease inhibitors using the cup-plate diffusion method. Compounds 6a and 6b were the most active with (IC50 = 0.58 ± 0.15 and 0.43 ± 0.09 µM), respectively, in comparison with lead compound I (IC50 = 1.13 ± 0.00 µM). Also, the designed compounds were docked into urease proteins (ID: 3LA4 and ID: 4UBP) using Open Eye® software to understand correctly about ligand–receptor interactions. The docking results revealed that the designed compounds can interact with the active site of the enzyme through multiple strong hydrogen bonds. Moreover, rapid overlay of chemical structures’ analysis was described to understand the 3D QSAR of synthesized compounds as urease inhibitors. The results emphasize the importance of polar thiosemicarbazide directly linked to 6-substituted quinolone moieties as promising antimicrobial urease inhibitors.

  一系列6-取代的喹啉-2-酮硫脲6a–j已被合成。目标化合物的结构通过不同的光谱和元素分析得到证实。所有设计的最终化合物分别对产生脲酶的R. mucilaginosa和Proteus mirabilis细菌作为真菌和细菌病原体的体外活性进行了评估。此外，所有化合物在体外采用杯盘扩散法作为潜在的脲酶抑制剂进行了测试。化合物6a和6b活性最强，分别为（IC50 = 0.58 ± 0.15和0.43 ± 0.09μM），与先导化合物I（IC50 = 1.13 ± 0.00μM）相比。此外，设计的化合物通过Open Eye®软件对接入脲酶蛋白（ID：3LA4和ID：4UBP），以正确理解配体-受体相互作用。对接结果显示，设计的化合物可以通过多个强氢键与酶的活性位点相互作用。此外，还描述了化学结构的快速叠加分析，以理解合成的化合物作为脲酶抑制剂的3D QSAR。结果强调了直接连接到6-取代喹诺酮部分的极性硫脲作为有前途的抗菌脲酶抑制剂的重要性。
• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107094A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括以下式的化合物：其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还包括通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。